ProPhase Labs, Inc. in brief
ProPhase Labs, Inc. is a listed company in the Pharmaceutical industry, based in New York, New York, USA. It was founded in 1989. Its last known market value was $87 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $4 M and a net loss of $15 M. It employs about 19 people. Its largest business segments by sales in 2025 were Consumer products (100%). Its shares trade under the symbol PRPH (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About ProPhase Labs, Inc.
We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.
Our wholly owned subsidiary, ProPhase BioPharma, Inc. is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand.
Previously we offered a broad array of COVID-19 related clinical diagnostic and testing services including polymerase chain reaction testing for COVID-19 and Influenza A and B as well as rapid antigen testing for COVID-19 through our wholly-owned subsidiary, ProPhase Diagnostics, Inc.. ProPhase Diagnostics’ two CLIA (Clinical Laboratory Improvement Amendments) certified laboratories are located in Old Bridge, New Jersey and Garden City, New York, respectively.
From the company's annual report filed with the US SEC: read the report
ProPhase Labs, Inc. timeline
- 1989
- 🏁· approximateFounded
- 1995
- 🔔· approximateInitial public offering on Nasdaq as PRPH
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed ProPhase Labs, Inc.Formerly Quigley Corp.
- 2021
- ⊕· approximateNebula Genomics became a subsidiary
- 2022
- 💰Record revenue of $123 millionFY2022, the highest of the 8 years on record.
- 2024
- ⊕· approximateDNA Complete became a subsidiary
Events of ProPhase Labs, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,451 (Jan 2020) · #3,650 (Jan 2021) · #4,280 (Jan 2022) · #3,910 (Dec 2022) · #4,019 (Jul 2023) · #3,793 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -585.2%
- Operating margin
- -415.9%
- Return on equity
- -640.2%
- Liabilities / assets
- 94.1%
- Net debt
- $1M
- Payout ratio
- 75.0%
- Revenue growth
- -35.9%
- R&D / revenue
- 2.5%
- Revenue per employee
- $228 K
- Profit per employee
- $-776 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4M | -35.9% | $-18M | $-15M | -339.6% |
| Dec 2024 | $7M | -80.6% | $-39M | $-53M | -788.2% |
| Dec 2023 | $35M | -71.5% | $-21M | $-17M | -48.0% |
| Dec 2022 | $123M | +55.2% | $24M | $18M | 15.1% |
| Dec 2021 | $79M | +444.7% | $10M | $6M | 7.9% |
| Dec 2020 | $15M | +46.9% | $-2M | $-2M | -14.6% |
| Dec 2019 | $10M | -24.8% | $-3M | $-3M | -31.9% |
| Dec 2018 | $13M | — | $-2M | $-2M | -13.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $-1.74 | — |
| Dec 2024 | $-18M | $1M | $-18M | $-26.68 | — |
| Dec 2023 | $-12M | $2M | $-14M | $-0.98 | — |
| Dec 2022 | $29M | $4M | $25M | $1.02 | — |
| Dec 2021 | $-14M | $4M | $-18M | $0.40 | $0.30 |
| Dec 2020 | $-3M | $2M | $-4M | $-0.18 | $0.00 |
| Dec 2019 | $-1M | $0M | $-1M | $-0.27 | — |
| Dec 2018 | $-2M | $0M | $-2M | $-0.15 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $1M (-19.2% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Aug 19, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportMaterial agreement · New financial obligation
- Jul 9, 202610-Q/AQuarterly report (amended) · period to Mar 2026
- Jul 7, 202610-Q/AQuarterly report (amended) · period to Mar 2026
- Jun 30, 202610-QQuarterly report · period to Mar 2026
- Jun 1, 202610-KAnnual report · period to Dec 2025
- Feb 13, 20268-KCurrent reportOther events
- Feb 13, 20268-KCurrent reportOther events
- Jan 27, 20268-KCurrent reportOther events
- Jan 23, 20268-KCurrent reportOther events
- Jan 23, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Jan 9, 20268-KCurrent reportOther events
Official filings of ProPhase Labs, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $4 M
- Operating income
- $-18 M
- Net income
- $-15 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $60 M
- Total liabilities
- $56 M
- Total equity
- $4 M
As of December-2025
Insider trading at ProPhase Labs, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Gift | -50,000 | — | — | 3.43 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Giftindirect | +50,000 | — | — | 150,000 | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Gift | -100,000 | — | — | 3.48 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Option exercise | +500,000 | $0.600 | $300 K | 3.85 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Shares withheld for tax | -268,337 | $8.180 | $2.2 M | 3.58 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Option exercise | +600,000 | $0.600 | $360 K | 3.67 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Shares withheld for tax | -319,231 | $9.360 | $3.0 M | 3.35 M | Form 4 |
| filed | Ted William KarkusCEO & CHAIRMAN, Director, 10% owner | Option exercise | +600,000 | $0.600 | $360 K | 3.39 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: ProPhase Labs, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2024 | Q4 2024 | $0M |
| Q3 2024 | Q3 2024 | $0M |
| Q2 2024 | Q2 2024 | $0M |
| Q1 2024 | Q1 2024 | $0M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $0.5M |
| Q4 2022 | Q4 2022 | $1M |
| Q3 2022 | Q3 2022 | $0.1M |
| Q2 2022 | Q2 2022 | $0M |
| Q1 2022 | Q1 2022 | $1.2M |
| Q4 2017 | Q4 2017 | $4.5M |
| Q3 2017 | Q3 2017 | $9.9M |
Trading halts
- 2025-12-20 00:50 UTC, code T3, resumed 14:00 UTC
- 2025-12-19 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 42 shares at $0.08
- : 1 shares at $0.12
- : 1 shares at $0.18
- : 1 shares at $0.17
- : 45 shares at $0.22
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
ProPhase Labs, Inc. scorecard#
Passes 0 of the 15 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 6
- ✗Revenue grew in the newest year-35.9%Revenue down 35.9% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-67.2%-67.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-67.2%-67.2% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-1.74 vs -26.68Diluted EPS -1.74 in fiscal 2025 against -26.68 the year before (report's currency).
- ✗Net income higher than five years earlier-$15 M-$15 M in fiscal 2025 against -$2 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$15 MNet income -$15 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-415.9%-415.9% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-271.4%-271.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-415.9%-415.9% in fiscal 2025 against 19.2% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.06 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-2.6×Operating income -2.6 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year324.4%Diluted shares up 324.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from ProPhase Labs, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -415.9% | 1.8% | |
| Net margin | -339.6% | -1.5% | |
| Return on equity | -271.5% | -0.9% | |
| Revenue growth, 3 years a year | -67.2% | 2.5% | |
| Revenue growth | -35.9% | 7.3% | |
| Free cash flow margin | -192.2% | 6.0% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 35.9% against the year before.
- Net loss of $15 million, the 3th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 324.4% in the year.
ProPhase Labs, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 4.3−35.8%100% | 6.8−80.6%100% | 35r44−71.5%100% | 123+55.2%100% | 79+445%100% | 15+47.0%100% | 9.9−24.8%100% | 13+33.0%100% | 9.9+135%100% | 4.2r21—100% | |
| Cost of revenue | 3.0−57.2%68.1% | 6.9−64.4%102% | 19r28−62.6%55.5% | 52+40.3%42.4% | 37+274%46.9% | 9.9+36.5%68.3% | 7.3−13.0%73.5% | 8.3+5.4%63.6% | 7.9+147%80.3% | 3.2r11—76.3% | |
| Gross profit | 1.4—31.9% | −0.2−101%−2.2% | 16r16−78.0%44.5% | 71+68.3%57.6% | 42+812%53.1% | 4.6+76.1%31.7% | 2.6−45.3%26.5% | 4.8+145%36.4% | 1.9+95.4%19.7% | 1.0r10—23.7% | |
| Research and development | 0.1−82.0%2.5% | 0.6−57.6%8.8% | 1.4r1.4+115%4.0% | 0.7+25.4%0.5% | 0.5−17.9%0.7% | 0.6+90.7%4.4% | 0.3−16.6%3.4% | 0.4−7.7%3.0% | 0.4+20.4%4.4% | 0.4r0.6—8.5% | |
| Selling and marketing | — | — | — | — | — | 1.3+23.5%8.9% | 1.0−5.9%10.6% | 1.1+58.4%8.4% | 0.7−58.9%7.1% | 1.7r7.1—40.4% | |
| General and administrative | 19−49.0%445% | 38+13.3%560% | 33r35−2.7%95.6% | 34+52.9%28.0% | 22+200%28.5% | 7.5r6.7+67.4%51.7% | 4.5−8.8%45.4% | 4.9+2.1%37.4% | 4.8+75.9%48.7% | 2.7r5.1—65.0% | |
| Operating expenses | 19−49.5%447% | 38+4.6%568% | 37r38−21.9%105% | 47+46.2%38.4% | 32+275%40.7% | 8.6r8.6+46.5%59.1% | 5.9−8.7%59.3% | 6.4+8.0%48.9% | 5.9+23.9%60.2% | 4.8r13—114% | |
| Operating income | −18—−415% | −39—−571% | −21r−22−190%−60.7% | 24+141%19.2% | 9.8—12.4% | −2.1r−2.1—−14.3% | −3.2—−32.8% | −1.6—−12.4% | −4.0—−40.4% | −2.7—−63.1% | |
| Interest and finance income | — | — | — | 0.2−76.2%0.1% | 0.6+935%0.8% | 0.1−53.4%0.4% | 0.1−20.4%1.3% | 0.2—1.3% | — | — | |
| Interest expense and finance costs | 6.9+107%160% | 3.4+163%49.5% | 1.3+66.9%3.6% | 0.8−33.4%0.6% | 1.1+289%1.5% | 0.3—2.0% | — | — | 0.1−74.6%0.5% | 0.2—5.1% | |
| Net interest income | — | — | — | — | — | — | — | 0.2−48.9%1.3% | 0.3—3.3% | −0.2—−5.0% | |
| Provision for credit losses | — | 0−100%0.0% | 0.1−98.5%0.3% | 6.2—5.0% | — | — | — | — | — | — | |
| Share of profit of associates | −0.2—−3.8% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.2—−4.0% | −0.0−280%−0.3% | 0.0—0.0% | 0—0.0% | — | — | — | — | 0.1−71.1%0.5% | 0.2—4.4% | |
| Income before tax | −23—−538% | −42—−625% | −22r−23−198%−64.0% | 23+332%18.7% | 5.3—6.7% | −2.3—−15.9% | −3.1—−31.4% | −1.5—−11.2% | −3.7—−37.1% | −4.0r−2.9—−95.2% | |
| Income tax | 0−100%0.0% | 7.2—106% | −6.0−235%−17.2% | 4.4—3.6% | −1.0−8167%−1.2% | 0.0—0.1% | — | 0.1—0.8% | −1.4r−18—−14.4% | — | |
| Income from continuing operations | −23—−538% | −50—−732% | −16—−46.8% | — | — | — | — | — | — | — | |
| Income from discontinued operations | 8.6—199% | −3.8—−56.7% | −0.4—−1.1% | — | — | 0.2—1.4% | −0.0—−0.4% | −0.2−100%−1.3% | 43r28+3664%434% | 1.1—27.1% | |
| Net income attributable to shareholders | −15—−339% | −53—−788% | −17−191%−48.0% | 18+194%15.1% | 6.3—7.9% | −2.1—−14.6% | −3.1—−31.9% | −1.7−104%−13.3% | 41r42—411% | −2.9—−68.2% | |
| Earnings per share, basic | -1.74—— | -26.68r-2.61—— | -0.98−184%— | 1.17+185%— | 0.41—— | -0.18—— | -0.27—— | -0.15−106%— | 2.61r2.69—— | -0.17—— | |
| Earnings per share, diluted | -1.74—— | -26.68r-2.61—— | -0.98−196%— | 1.02+155%— | 0.40—— | -0.18—— | -0.27—— | -0.15−106%— | 2.59r2.67—— | -0.17—— | |
| Shares, weighted average (basic) | 8.5+324%— | 2.0r20−88.4%— | 17+8.6%— | 16+4.4%— | 15+30.8%— | 12—— | — | 11−26.8%— | 16r0.0−8.9%— | 17r0.0—— | |
| Shares, weighted average (diluted) | 8.5+324%— | 2.0r20−88.4%— | 17−7.7%— | 19+1.4%— | 18+58.6%— | 12+0.3%— | 12+1.5%— | 11−27.4%— | 16r0.0−8.1%— | 17r17—— | |
| Dividends per share | — | — | — | — | 0.30—— | 0.00—— | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.1−86.7%0.2% | 0.7−57.9%1.1% | 1.6−82.3%1.8% | 9.1+8.3%10.4% | 8.4+23.4%9.4% | 6.8+1471%21.7% | 0.4−72.1%3.5% | 1.6−51.0%7.5% | 3.2+620%9.4% | 0.4—3.4% | |
| Short-term investments | 0−100%0.0% | 3.1r00.0%4.9% | 3.1−62.5%3.4% | 8.3−5.1%9.5% | 8.8+436%9.8% | 1.6+77.0%5.2% | 0.9−86.2%7.5% | 6.7−64.4%32.2% | 19—55.8% | — | |
| Receivables | 1.5−92.3%2.6% | 20−44.0%31.7% | 36r36−3.3%39.0% | 37−1.7%42.3% | 38+1095%42.2% | 3.2+57.0%10.0% | 2.0−32.3%16.4% | 3.0+52.6%14.3% | 1.9−66.3%5.8% | 5.8—45.1% | |
| Inventory | 0.1−93.9%0.1% | 1.1−50.1%1.8% | 2.3r3.8−42.4%2.5% | 4.0−13.6%4.5% | 4.6+51.4%5.2% | 3.0+108%9.7% | 1.5−23.3%11.9% | 1.9+24.3%9.2% | 1.5−44.0%4.5% | 2.7—21.4% | |
| Other current assets | 1.5−44.4%2.4% | 2.6+33.8%4.1% | 2.0r2.2−17.4%2.1% | 2.4+58.2%2.7% | 1.5+20.8%1.7% | 1.2r1.2+307%3.9% | 0.3+2.7%2.5% | 0.3−38.5%1.4% | 0.5−29.3%1.4% | 0.7—5.3% | |
| Current assets | 3.2−89.7%5.3% | 31−35.6%48.5% | 48−21.8%51.8% | 61−0.8%69.4% | 61+286%68.7% | 16+59.7%50.6% | 9.9−45.5%81.0% | 18−35.8%87.9% | 28r29+195%84.4% | 9.6—75.2% | |
| Property, plant and equipment | 2.0−72.9%3.4% | 7.5−27.4%11.9% | 10r13+41.7%11.2% | 7.3+22.5%8.3% | 5.9+66.2%6.7% | 3.6+53.6%11.4% | 2.3−6.8%19.0% | 2.5−8.9%12.1% | 2.7−13.6%8.1% | 3.2—24.8% | |
| Right-of-use (leased) assets | 0−100%0.0% | 4.1−10.0%6.5% | 4.6+12.6%5.0% | 4.1−7.8%4.6% | 4.4−7.0%4.9% | 4.7—15.1% | — | — | — | — | |
| Goodwill | 4.0−24.1%6.6% | 5.20.0%8.3% | 5.2−8.4%5.7% | 5.70.0%6.5% | 5.7+534%6.4% | 0.9—2.9% | — | — | — | — | |
| Other intangible assets | 7.2−26.5%12.0% | 9.8−20.9%15.4% | 12+45.5%13.4% | 8.5−21.9%9.7% | 11+779%12.2% | 1.2—3.9% | — | — | — | — | |
| Investments in associates | 43—72.6% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Total assets | 60−5.3%100% | 63−31.2%100% | 92+4.9%100% | 88−1.8%100% | 89+184%100% | 31+156%100% | 12−40.8%100% | 21−38.4%100% | 34r34+163%100% | 13—100% | |
| Accounts payable | — | 14+58.7%21.7% | 8.6r9.4+46.4%9.4% | 5.9−16.0%6.7% | 7.0+86.3%7.9% | 3.8+773%12.0% | 0.4−1.1%3.5% | 0.4−22.2%2.1% | 0.6−73.9%1.7% | 2.2—16.8% | |
| Current liabilities | 53+65.2%88.7% | 32+54.1%50.8% | 21+29.7%22.7% | 16+3.5%18.3% | 16+147%17.4% | 6.3+575%20.0% | 0.9−78.0%7.6% | 4.2+134%20.4% | 1.8r1.1−73.5%5.4% | 6.8—53.4% | |
| Long-term debt | — | — | 2.9—3.2% | 0—0.0% | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 0−100%0.0% | 3.8−11.2%6.0% | 4.2−0.5%4.6% | 4.3+1.5%4.9% | 4.2−4.6%4.7% | 4.4—14.0% | — | — | — | — | |
| Non-current liabilities | 3.3−86.2%5.5% | 24+9.3%37.5% | 22+173%23.6% | 7.9−47.6%9.1% | 15+4.0%17.0% | 15+13132%46.3% | 0.1—0.9% | — | — | — | |
| Total liabilities | 56+0.9%94.1% | 56+31.3%88.4% | 43+77.1%46.3% | 24−21.7%27.4% | 31+47.1%34.3% | 21+1899%66.4% | 1.0−75.4%8.5% | 4.2—20.4% | — | — | |
| Retained earnings | −73—−122% | −58—−92.4% | −5.0−143%−5.5% | 12+345%13.4% | 2.6—3.0% | −3.6—−11.6% | −1.5−133%−12.3% | 4.5−78.3%21.9% | 21r22—62.1% | −20—−154% | |
| Shareholders' equity | 3.5−52.3%5.9% | 7.4−85.1%11.6% | 49−22.4%53.7% | 64+8.5%72.6% | 59+455%65.7% | 11−6.0%33.6% | 11−31.9%91.5% | 17−48.2%79.6% | 32r33+434%94.6% | 6.0—46.6% | |
| Total equity | 3.5−52.3%5.9% | 7.4—11.6% | — | — | — | — | — | — | — | — | |
| Total liabilities and equity | 60−5.3%100% | 63−31.2%100% | 92+4.9%100% | 88−1.8%100% | 89+184%100% | 31+156%100% | 12−40.8%100% | 21−38.4%100% | 34r34+163%100% | 13—100% | |
| Shares outstanding | 9.0+200%— | 3.0r30−83.4%— | 18+11.3%— | 16+4.7%— | 15+33.5%— | 12—— | — | — | — | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 4.8−21.9%111% | 6.2+2.3%91.4% | 6.1r6.3+28.2%17.3% | 4.7+45.9%3.8% | 3.2+620%4.1% | 0.4+12.8%3.1% | 0.4+3.9%4.0% | 0.4+13.6%2.9% | 0.3−20.9%3.4% | 0.4—10.1% | |
| Share-based compensation | 1.9−48.0%43.6% | 3.6+2.9%53.7% | 3.5−11.3%10.1% | 4.0+25.2%3.2% | 3.2+118%4.0% | 1.5+96.1%10.1% | 0.7+17.4%7.5% | 0.6r0.6+713%4.8% | 0.1+7700%0.8% | 0.0—0.0% | |
| Cash from operating activities | −8.3—−192% | −18—−259% | −12r−11−142%−34.0% | 29—23.3% | −14—−17.2% | −2.6r2.6—−17.9% | −0.8—−8.5% | −2.1—−16.1% | −2.8—−28.8% | −0.5—−11.2% | |
| Capital expenditure | 0—0.0% | −0.9—−13.4% | −2.1r−3.2—−6.0% | −3.9—−3.2% | −4.2—−5.4% | −1.7—−11.6% | −0.2—−2.3% | −0.1—−1.1% | −0.2—−2.1% | −0.7—−15.5% | |
| Acquisitions, net of cash acquired | — | 0—0.0% | −2.9—−8.3% | 0—0.0% | −9.1—−11.5% | — | — | — | — | — | |
| Cash from investing activities | 0.9−62.0%21.2% | 2.4—35.8% | −1.4—−3.9% | −2.1—−1.7% | −20—−24.9% | −1.0−118%−7.0% | 5.5−53.3%56.1% | 12−45.5%90.4% | 22—221% | −0.7—−15.5% | |
| Debt issued | — | — | — | — | — | 10—68.9% | — | — | — | — | |
| Debt repaid | — | — | — | — | — | — | — | — | — | −0.1—−2.4% | |
| Shares issued | 3.6—81.9% | 0r7.6—0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Shares bought back | — | 0—0.0% | −0.6—−1.7% | −2.2—−1.8% | −0.9—−1.2% | — | — | — | −16—−165% | — | |
| Dividends paid | — | — | 0—0.0% | −9.4—−7.6% | −4.5—−5.8% | — | −5.8—−59.0% | −12—−89.1% | — | — | |
| Cash from financing activities | 6.8−51.8%157% | 14+146%210% | 5.8—16.5% | −26−174%−21.2% | 35+252%44.4% | 10.0—68.8% | −5.8—−59.0% | −11—−86.6% | −16—−164% | −0.1—−2.4% | |
| Change in cash | −0.6—−13.5% | −0.9—−13.8% | −7.5r−7.0−1763%−21.4% | 0.5−75.5%0.4% | 1.8−71.1%2.3% | 6.4—44.0% | −1.1—−11.3% | −1.6−159%−12.3% | 2.7—27.7% | −1.2—−29.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 3,847−31.2%100% | 1,011−18.9%100% | 1,169r478−18.3%100% | 784*−47.5%100% | 883−37.6%100% | 1,247−17.1%100% | 1,431−39.3%100% | 1,494*—100% | 1,416r3,146−83.1%100% | 1,504r2,474—100% | 2,356r3,634—100% | — | 8,365—100% | |
| Cost of revenue | 3,202−24.9%83.2% | 785+53.0%77.6% | 874r311−3.4%74.8% | 537*−67.3%68.5% | 1,006−16.2%114% | 513−69.1%41.1% | 905−62.5%63.2% | 1,644*—110% | 1,201r3,311−80.1%84.8% | 1,659r2,950—110% | 2,416r4,067—103% | — | 6,038—72.2% | |
| Gross profit | 645−51.3%16.8% | 226−69.2%22.4% | 295r167−43.9%25.2% | 247*—31.5% | −123−157%−13.9% | 734—58.9% | 526—36.8% | −150r924*—−10.0% | 215r−165−90.8%15.2% | −155r−476—−10.3% | −60r−433—−2.5% | −3,739r−3,056*—— | 2,327—27.8% | |
| Research and development | — | — | — | 0*−100%0.0% | 6.0−95.1%0.7% | 4.0−97.1%0.3% | 97−64.3%6.8% | 60r61*−76.7%4.0% | 122−71.5%8.6% | 140r139—9.3% | 272—11.5% | 258r274*—— | 428—5.1% | |
| General and administrative | 16,200−50.0%421% | 2,871−37.9%284% | 2,721r2,772−33.5%233% | 5,973*−65.0%762% | 4,635−29.5%525% | 4,624−33.3%371% | 4,092−43.9%286% | 17,080r15,430*+145%1143% | 6,573r7,650−20.3%464% | 6,933r7,212—461% | 7,299r7,593—310% | 6,962r8,022*—— | 8,245—98.6% | |
| Operating expenses | 16,206−50.4%421% | 2,871−38.0%284% | 2,721r2,772−35.0%233% | 5,973*−65.2%762% | 4,641−30.7%526% | 4,628−34.6%371% | 4,189−44.7%293% | 17,140r15,491*+137%1147% | 6,695r7,772−24.0%473% | 7,073r7,351—470% | 7,571r7,865—321% | 7,220r8,296*—— | 8,805—105% | |
| Operating income | −15,561—−404% | −2,645—−262% | −2,426r−2,605—−208% | −5,726*—−730% | −4,764—−540% | −3,894—−312% | −3,663—−256% | −17,290r−14,567*—−1157% | −6,480r−7,937—−458% | −7,228r−7,827—−481% | −7,631r−8,298—−324% | −10,959r−11,352*—— | −6,478—−77.4% | |
| Interest expense and finance costs | 7,249+106%188% | 791+34.8%78.2% | 651+20.8%55.7% | 4,258*+205%543% | 1,549+56.0%175% | 587+12.5%47.1% | 539+4.7%37.7% | 1,394r1,034*+182%93.3% | 993r1,158+261%70.1% | 522r643—34.7% | 515—21.9% | 494*—— | 275—3.3% | |
| Provision for credit losses | — | — | — | — | — | — | — | 0*−100%0.0% | 0*−100%0.0% | — | — | 17*—— | 268*—3.2% | |
| Share of profit of associates | — | −47—−4.6% | −225—−19.2% | — | — | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −244—−6.3% | 59—5.8% | −129—−11.0% | −174*—−22.2% | 0—0.0% | 0—0.0% | −45—−3.1% | 0r−30*−100%0.0% | 0—0.0% | 0r30—0.0% | −18—−0.8% | 142*—— | −33—−0.4% | |
| Income before tax | −21,856—−568% | −3,039—−301% | −3,801r−3,980—−325% | −8,020*—−1023% | −6,996—−792% | −3,693—−296% | −4,678—−327% | −19,017r−15,964*—−1273% | −7,473r−9,095—−528% | −7,750r−8,440—−515% | −8,090r−8,831—−343% | −11,263r−11,665*—— | −6,785—−81.1% | |
| Income tax | 607−95.3%15.8% | 12−98.5%1.2% | 1,374—118% | −622*−104%−79.3% | −157—−17.8% | 779—62.5% | 0—0.0% | 14,556*—974% | −2,508—−177% | −2,287—−152% | −2,566—−109% | −2,914*—— | −1,644—−19.7% | |
| Income from continuing operations | −22,463—−584% | −3,051—−302% | −5,175r−5,354—−443% | −7,398*—−944% | −6,839—−775% | −4,472—−359% | −4,678—−327% | −33,573*—−2247% | −4,965—−351% | −5,463—−363% | −5,524—−234% | — | — | |
| Income from discontinued operations | — | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | 8,644—604% | −786*—−52.6% | −1,622—−115% | −690—−45.9% | −741—−31.5% | — | — | |
| Net income including minority interests | — | −3,051—−302% | −5,175r−5,354−230%−443% | — | — | −4,472—−359% | 3,966—277% | — | — | — | — | — | — | |
| Net income attributable to shareholders | −22,463—−584% | −3,051—−302% | −5,175r−5,354−230%−443% | −7,398*—−944% | −6,839—−775% | −4,472—−359% | 3,966—277% | −34,359*—−2300% | −6,587—−465% | −6,153—−409% | −6,265—−266% | −8,751*—— | −5,141—−61.5% | |
| Earnings per share, basic | — | -0.22—— | -0.42r-0.43−137%— | — | -0.16—— | -1.08r-0.11—— | 1.13r0.11—— | — | -0.35—— | -0.33—— | -0.36r-0.35—— | — | -0.30—— | |
| Earnings per share, diluted | — | -0.22—— | -0.42r-0.43−137%— | — | -0.16—— | -1.08r-0.11—— | 1.13r0.11—— | — | -0.35—— | -0.33—— | -0.36r-0.35—— | — | -0.30—— | |
| Shares, weighted average (basic) | 14+237%— | 14+237%— | 12+250%— | — | 42+118%— | 4.2r42−78.0%— | 3.5r35−79.5%— | — | 19+11.1%— | 19—— | 17r18—— | — | 17—— | |
| Shares, weighted average (diluted) | 14+237%— | 14+237%— | 12+250%— | — | 42+118%— | 4.2r42−78.0%— | 3.5r35−79.5%— | — | 19+11.1%— | 19—— | 17r18—— | — | 17—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 20—0.0% | 20−88.2%0.0% | 31−64.8%0.1% | 90−86.7%0.2% | 405−19.2%0.6% | 169−90.5%0.4% | 88−92.5%0.2% | 678−57.9%1.1% | 501−28.6%0.5% | 1,780—1.9% | 1,175—1.3% | 1,609—1.8% | 702—0.8% | |
| Short-term investments | — | — | — | 0−100%0.0% | — | 2.0+100%0.0% | — | 3,127r00.0%4.9% | 2.0−99.9%0.0% | 1.0—0.0% | 58—0.1% | 3,127—3.4% | 2,565—2.8% | |
| Receivables | 1,543—2.7% | 1,543−92.3%2.7% | 1,543−92.4%2.6% | 1,536−92.3%2.6% | 3,284−89.6%5.0% | 20,086−39.0%47.8% | 20,204−42.5%40.3% | 20,058−44.0%31.7% | 31,638−18.1%34.5% | 32,937—35.2% | 35,116—39.0% | 35,814r36,313—39.0% | 38,642—42.1% | |
| Inventory | 70—0.1% | 70−91.6%0.1% | 70−93.9%0.1% | 70−93.9%0.1% | 266−93.3%0.4% | 830−78.5%2.0% | 1,145−69.5%2.3% | 1,143−50.1%1.8% | 3,966−21.5%4.3% | 3,867—4.1% | 3,758—4.2% | 2,291r3,841—2.5% | 5,054—5.5% | |
| Other current assets | 1,169—2.0% | 1,169−66.4%2.0% | 1,206r1,469−63.8%2.1% | 1,454−44.4%2.4% | 3,818−31.0%5.8% | 3,484−29.9%8.3% | 3,333−23.9%6.7% | 2,615+33.8%4.1% | 5,535+95.5%6.0% | 4,973—5.3% | 4,377—4.9% | 1,955r2,155—2.1% | 2,831—3.1% | |
| Current assets | 2,802—4.9% | 2,802−88.6%4.9% | 2,850r3,113−88.5%4.9% | 3,150−89.7%5.3% | 7,773−81.6%11.8% | 24,571−44.3%58.4% | 24,770−45.0%49.4% | 30,637−35.6%48.5% | 42,235−15.2%46.0% | 44,143—47.1% | 45,045—50.0% | 47,585—51.8% | 49,794—54.3% | |
| Property, plant and equipment | 1,392—2.4% | 1,392−61.1%2.4% | 1,709−74.0%2.9% | 2,032−72.9%3.4% | 2,349−83.0%3.6% | 3,581−76.8%8.5% | 6,567−48.7%13.1% | 7,501−27.4%11.9% | 13,851+5.2%15.1% | 15,420—16.5% | 12,797—14.2% | 10,330r12,898—11.2% | 13,163—14.4% | |
| Right-of-use (leased) assets | — | — | — | 0−100%0.0% | 0−100%0.0% | 45−99.0%0.1% | 3,994−10.5%8.0% | 4,115−10.0%6.5% | 4,234−9.5%4.6% | 4,350—4.6% | 4,462—5.0% | 4,572—5.0% | 4,680—5.1% | |
| Goodwill | 3,968—6.9% | 3,968−24.1%6.9% | 3,968−24.1%6.8% | 3,968−24.1%6.6% | 3,968−24.1%6.0% | 5,2310.0%12.4% | 5,2310.0%10.4% | 5,2310.0%8.3% | 5,2310.0%5.7% | 5,231—5.6% | 5,231—5.8% | 5,231—5.7% | 5,231—5.7% | |
| Other intangible assets | 5,876—10.2% | 5,876−30.5%10.2% | 6,522−28.4%11.2% | 7,167−26.5%12.0% | 7,813−24.8%11.9% | 8,459−23.4%20.1% | 9,104−22.1%18.2% | 9,750−20.9%15.4% | 10,396−20.1%11.3% | 11,041—11.8% | 11,687—13.0% | 12,333—13.4% | 13,015—14.2% | |
| Investments in associates | 43,219—75.3% | 43,219—75.3% | 43,266—74.0% | 43,491—72.6% | 43,657—66.4% | — | — | 0—0.0% | — | — | — | — | — | |
| Total assets | 57,409—100% | 57,409+36.6%100% | 58,467r58,730+16.7%100% | 59,871−5.3%100% | 65,702−28.4%100% | 42,041−55.1%100% | 50,111−44.3%100% | 63,200−31.2%100% | 91,808+0.1%100% | 93,678—100% | 90,032—100% | 91,927—100% | 91,710—100% | |
| Accounts payable | — | — | — | — | — | 15,032+10.3%35.8% | 13,326+13.3%26.6% | 13,717+58.7%21.7% | 15,459+183%16.8% | 13,628—14.5% | 11,759—13.1% | 8,644r9,383—9.4% | 5,467—6.0% | |
| Current liabilities | 58,087—101% | 58,087+127%101% | 55,666r56,108+131%95.2% | 53,081+65.2%88.7% | 55,287+92.7%84.1% | 25,626−8.5%61.0% | 24,052+0.6%48.0% | 32,134+54.1%50.8% | 28,698+74.9%31.3% | 28,012—29.9% | 23,907—26.6% | 20,857—22.7% | 16,406—17.9% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | 2,924—3.2% | — | |
| Lease liabilities (non-current) | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 3,695−10.4%7.4% | 3,762−11.2%6.0% | 3,663−15.7%4.0% | 4,005—4.3% | 4,122—4.6% | 4,237—4.6% | 4,345—4.7% | |
| Non-current liabilities | 2,433—4.2% | 2,433−51.1%4.2% | 3,236−70.4%5.5% | 3,282−86.2%5.5% | 3,554−85.8%5.4% | 4,979−76.9%11.8% | 10,941−48.5%21.8% | 23,713+9.3%37.5% | 24,984+32.4%27.2% | 21,590—23.0% | 21,258—23.6% | 21,687—23.6% | 18,876—20.6% | |
| Total liabilities | 60,520—105% | 60,520+97.7%105% | 58,902r59,344+68.3%101% | 56,363+0.9%94.1% | 58,841+9.6%89.6% | 30,605−38.3%72.8% | 34,993−22.5%69.8% | 55,847+31.3%88.4% | 53,682+52.2%58.5% | 49,602—52.9% | 45,165—50.2% | 42,544—46.3% | 35,282—38.5% | |
| Retained earnings | −81,362—−142% | −81,362—−142% | −78,311r−78,490—−134% | −73,136—−122% | −65,738—−100% | −58,899—−140% | −54,427—−109% | −58,393—−92.4% | −24,034−746%−26.2% | −17,447—−18.6% | −11,294—−12.5% | −5,029—−5.5% | 3,722—4.1% | |
| Shareholders' equity | −3,111—−5.4% | −3,111−127%−5.4% | −435r−614−103%−0.7% | 3,508−52.3%5.9% | 6,861−82.0%10.4% | 11,436−74.1%27.2% | 15,118−66.3%30.2% | 7,353−85.1%11.6% | 38,126−32.4%41.5% | 44,076—47.1% | 44,867—49.8% | 49,383—53.7% | 56,428—61.5% | |
| Total equity | −3,111—−5.4% | −3,111−127%−5.4% | −435r−614−103%−0.7% | 3,508−52.3%5.9% | — | 11,436—27.2% | 15,118—30.2% | 7,353—11.6% | — | — | — | — | — | |
| Total liabilities and equity | 57,409—100% | 57,409+36.6%100% | 58,467r58,730+16.7%100% | 59,871−5.3%100% | 65,702−28.4%100% | 42,041−55.1%100% | 50,111−44.3%100% | 63,200−31.2%100% | 91,808+0.1%100% | 93,678—100% | 90,032—100% | 91,927—100% | 91,710—100% | |
| Shares outstanding | 14—— | 14−66.3%— | 14−66.3%— | 9.0+200%— | 42+118%— | 42+118%— | 42+130%— | 3.0r30−83.4%— | 19+5.7%— | 19—— | 18—— | 18—— | 18—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3,246−41.5%84.4% | 623−38.3%61.6% | 962−35.1%82.3% | 963*−36.8%123% | 698−54.4%79.0% | 1,010−34.1%81.0% | 1,482−7.7%104% | 1,523r494*−5.7%102% | 1,532r1,522−40.4%108% | 1,532—102% | 1,605r1,686—68.1% | 1,615r1,842*—— | 2,571—30.7% | |
| Share-based compensation | 1,598−28.6%41.5% | 375*−25.0%37.1% | 390−25.1%33.4% | 433*−29.8%55.2% | 400−33.3%45.3% | 500−37.5%40.1% | 521−67.2%36.4% | 617*−8.7%41.3% | 600−33.3%42.4% | 800—53.2% | 1,589—67.4% | 676*—— | 900r700—10.8% | |
| Cash from operating activities | −5,542—−144% | −78*—−7.7% | −748—−64.0% | −1,230*—−157% | −3,486*—−395% | −247*—−19.8% | −3,381—−236% | −3,518r−3,571*—−235% | −4,038r−4,030*—−285% | −4,842r−4,818*—−322% | −5,140r−5,119—−218% | −753r−213*—— | −4,654*—−55.6% | |
| Capital expenditure | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −40*—−2.7% | — | 0r−26*—0.0% | −867r−939—−36.8% | −239r−1,310*—— | −668*—−8.0% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—— | 0*—0.0% | |
| Cash from investing activities | 12−98.5%0.3% | 0*−100%0.0% | 12−98.6%1.0% | 0*—0.0% | 0*—0.0% | 67*−46.0%5.4% | 853−65.0%59.6% | −40*—−2.7% | −97*−129%−6.9% | 124*—8.2% | 2,435—103% | −1,264*—— | 332*—4.0% | |
| Shares issued | 41—1.1% | 0*−100%0.0% | 41−98.7%3.5% | 0*—0.0% | 0*—0.0% | 280*−93.9%22.5% | 3,278—229% | −4,624r2,970*—−310% | 0*—0.0% | 4,624*—307% | 0—0.0% | 0*—— | 0*—0.0% | |
| Shares bought back | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—— | 0*—0.0% | |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—0.0% | |
| Cash from financing activities | 5,381−38.8%140% | 67*−74.3%6.6% | 677−65.1%57.9% | 915*−75.5%117% | 3,722*+30.3%422% | 261*−95.1%20.9% | 1,938−14.7%135% | 3,735*+27.7%250% | 2,856*+138%202% | 5,323*—354% | 2,271—96.4% | 2,924*—— | 1,200*—14.3% | |
| Change in cash | −149—−3.9% | −11*−114%−1.1% | −59—−5.0% | −315*−278%−40.2% | 236*—26.7% | 81*−86.6%6.5% | −590—−41.2% | 177r124*−80.5%11.8% | −1,279r−1,271*—−90.3% | 605r629*—40.2% | −434r−413—−18.4% | 907r1,447*—— | −3,122*—−37.3% | |
| Report | Worked out | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-Q/A | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What ProPhase Labs, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Consumer products$4 M100%-36%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at ProPhase Labs, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 3 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 2
| Filed | What happened | Filing |
|---|---|---|
| Material agreementNew debt | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Bylaws or fiscal year changed | 8-K/A | |
| Bylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K/A | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementBylaws or fiscal year changedShareholder vote | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 6, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2025 | $3 M | Private placement after listing | $2 to $10 million | 2 | debt, options | SEC |
| Jun 2025 | $1 M | Private placement after listing | Under $2 million | 2 | debt, options | SEC |
| Dec 2015 | $2 M | Private placement after listing | Under $2 million | 2 | debt, options | SEC |
| Mar 2010 | $3 M | No. 1 | $2 to $10 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at ProPhase Labs, Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $97 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Research and Development DirectorBiochemists and Biophysicists | 1 | $97 K |
Where: Garden City, NY 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ProPhase Labs, Inc.
How ProPhase Labs, Inc. compares in Pharmaceutical
- Revenue$4 M · higher than 4% of 324
- Net margin-585.2% · higher than 1% of 313
- Revenue growth-35.9% · higher than 3% of 107
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| ProPhase Labs, Inc.🇺🇸 | $87 M | — | -585.2% | -35.9% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at ProPhase Labs, Inc.? Verify and update this profile — free
Show ProPhase Labs, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.